Report scope. This 2026 Drug Asset Due Diligence Report evaluates Temtokibart as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Temtokibart is a Monoclonal antibody associated with IL-22R and a global highest development stage of Phase 2. The lead disclosed indication is Moderate Atopic Dermatitis. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Temtokibart
- Target: IL-22R
- Lead indication: Moderate Atopic Dermatitis
- Highest phase: Phase 2
- Matched trials: 5
- Matched result records: 6
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the Temtokibart diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Temtokibart, the MCP profile identifies IL-22R as the primary target context and Moderate Atopic Dermatitis as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Temtokibart diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05923099 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT05470114 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT05099133 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT04922021 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT03514511 | Phase 1 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Temtokibart diligence evidence.
3. Clinical readouts: what is known
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-site, Parallel-group, Dose-finding Trial to Evaluate the Efficacy and Safety of Different Doses of Subcutaneously Administered LEO 138559 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Study: NCT05923099 (CTgov). Phase: Phase 2. Enrollment: 262. Published: 2026-02-12.
Percent Change in Eczema Area and Severity Index (EASI) Score(LS Mean) = -61.15 percent of change (95%CI, -71.38 to -50.91) | Percent Change in Eczema Area and Severity Index (EASI) Score(LS Mean) = -57.05 percent of change (95%CI, -67.13 to -46.96)
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis
Study: NCT05923099 (BusinessWire). Phase: Phase 2. Enrollment: Not disclosed. Published: 2025-05-09.
EASI(16-week) = achieved positive results for the primary endpoint. | EASI(16-week) = achieved positive results for the primary endpoint.
A Randomized, Double-blinded, Active Comparator-controlled, 16-week, Single-site, Exploratory, Mechanistic Trial to Assess the Effect of LEO 138559 on the Molecular Signature and Safety in Adults With Moderate to Severe Atopic Dermatitis.
Study: NCT05470114 (CTgov). Phase: Phase 2. Enrollment: 13. Published: 2025-02-14.
Keratinocytes S100A7(Mean) = 0.212 Fold | Keratinocytes S100A7(Mean) = 0.043 Fold
LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting
Study: NCT05470114 (PipelineReview). Phase: Phase 2. Enrollment: 12. Published: 2024-09-30.
biomarker(PCA and UCA; 1-week): P-Value = <0.0001 | biomarker(PCA and UCA; 1-week): P-Value = <0.0001
Efficacy and safety of IL-22RA1 inhibition in patients with moderate-to-severe atopic dermatitis: results from a Phase 2a monotherapy trial
Study: NCT04922021 (EADV2023). Phase: Phase 2. Enrollment: Not disclosed. Published: 2023-10-11.
EASI100 = 20.9 % | EASI-75 = 13.7 %
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD).
Study: NCT04922021 (CTgov). Phase: Phase 2. Enrollment: 58. Published: 2023-07-24.
Change in EASI Score From Baseline to Week 16(Mean) = -15.3 Point | Change in EASI Score From Baseline to Week 16(Mean) = -3.5 Point
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Temtokibart diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Temtokibart against approved therapies and clinical competitors in Moderate Atopic Dermatitis, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Temtokibart diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2015-05-22 | ArGEN-X pairs up with Leo Pharma in a $116M dermatology deal | Active | License | Disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Temtokibart diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
